Clinical Trial Update: Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. [Phase 2]

View source ↗

Summary

Open-label phase 2 trial of asciminib for chronic myeloid leukemia in chronic or accelerated phase with the T315I mutation who are resistant, intolerant, or ine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Asciminib (Scemblix) (asciminib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia (CML) | Phase 2 | Status: RECRUITING